Abstract
In patients presenting with a clinically isolated syndrome, MRI can support and substitute clinical information in the diagnosis of multiple sclerosis by showing disease dissemination in space and time and by helping to exclude disorders that can mimic multiple sclerosis. MRI criteria were first included in the diagnostic work-up for multiple sclerosis in 2001, and since then several modifications to the criteria have been proposed in an attempt to simplify lesion-count models for showing disease dissemination in space, change the timing of MRI scanning to show dissemination in time, and increase the value of spinal cord imaging. Since the last update of these criteria, new data on the use of MRI to establish dissemination in space and time have become available, and MRI technology has improved. State-of-the-art MRI findings in these patients were discussed in a MAGNIMS workshop, the goal of which was to provide an evidence-based and expert-opinion consensus on proposed modifications to MRI criteria for the diagnosis of multiple sclerosis.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 292-303 |
| Number of pages | 12 |
| Journal | The Lancet Neurology |
| Volume | 15 |
| Issue number | 3 |
| DOIs | |
| State | Published - 2016 |
ASJC Scopus subject areas
- Clinical Neurology
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
MRI criteria for the diagnosis of multiple sclerosis : MAGNIMS consensus guidelines. / Filippi, Massimo; Rocca, Maria A.; Ciccarelli, Olga; De Stefano, Nicola; Evangelou, Nikos; Kappos, Ludwig; Rovira, Alex; Sastre-Garriga, Jaume; Tintorè, Mar; Frederiksen, Jette L.; Gasperini, Claudio; Palace, Jacqueline; Reich, Daniel S.; Banwell, Brenda; Montalban, Xavier; Barkhof, Frederik.
In: The Lancet Neurology, Vol. 15, No. 3, 2016, p. 292-303.Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - MRI criteria for the diagnosis of multiple sclerosis
T2 - MAGNIMS consensus guidelines
AU - Filippi, Massimo
AU - Rocca, Maria A.
AU - Ciccarelli, Olga
AU - De Stefano, Nicola
AU - Evangelou, Nikos
AU - Kappos, Ludwig
AU - Rovira, Alex
AU - Sastre-Garriga, Jaume
AU - Tintorè, Mar
AU - Frederiksen, Jette L.
AU - Gasperini, Claudio
AU - Palace, Jacqueline
AU - Reich, Daniel S.
AU - Banwell, Brenda
AU - Montalban, Xavier
AU - Barkhof, Frederik
N1 - Funding Information: The workshop that formed the basis of this Review was supported by an unrestricted educational grant from Novartis. The funding source had no role in the preparation of this article. We are very grateful to Douglas Arnold (Brain Imaging Center, Montreal Neurological Institute, McGill University, Montreal, QC, Canada) for his fruitful discussion during the meeting and his subsequent thoughtful comments on the manuscript. We also thank Martina Absinta (Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy) and Pascal Sati (Translational Neuroradiology Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA) for providing figures 3 and 4 . LK has received research grants from the Swiss MS Society, the Swiss National Research Foundation, and the European Union. JP has received research grants from the Multiple Sclerosis Society UK, and the Guthy-Jackson Foundation. FB receives research support from Neugrid4you (FP7 European committee) and the Dutch Foundation for MS Research—centre grant 2010–14. Funding Information: Travel expenses for the workshop were paid by Novartis through a provider. The speakers did not receive direct reimbursement. MF serves on scientific advisory boards for Teva Pharmaceutical Industries, has received compensation for consulting services and speaking activities from Biogen Idec, Excemed, Novartis, and Teva Pharmaceutical Industries, and receives research support from Biogen Idec, Teva Pharmaceutical Industries, and Novartis. MAR has received speakers honoraria from Biogen Idec, Novartis, Genzyme, Sanofi-Aventis, and Excemed. OC serves as a consultant for GE, Biogen Idec, and Novartis, and all the payments are made to the institution (Queen Square MS Centre, UCL Institute of Neurology, London, UK). NDS has received honoraria from Schering, Biogen Idec, Teva Pharmaceutical Industries, Novartis, Genzyme, and Merck Serono SA for consulting services, speaking, and travel support. He serves on advisory boards for Biogen Idec, Merck Serono SA, and Novartis. NE has received honoraria from Biogen Idec, Novartis, and Genzyme for consulting services, speaking, and travel support. He serves on advisory boards for Biogen Idec, Merck Serono, and Novartis. LK's institution (University Hospital Basel) has received in the past 3 years and used exclusively for research support steering committee, advisory board, and consultancy fees from Actelion, Addex, Bayer HealthCare, Biogen Idec, Biotica, Genzyme, Eli-Lilly & Company, Merck, Mitsubishi, Novartis, Ono Pharma, Pfizer, Receptos, Sanofi-Aventis, Santhera, Siemens, Teva Pharmaceutical Industries, UCB, and Xenoport, speaker fees from Bayer HealthCare, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis, and Teva Pharmaceutical Industries, support of educational activities from Bayer HealthCare, Biogen Idec, CSL Behring, Genzyme, Merck Serono, Novartis, Sanofi-Aventis, and Teva Pharmaceutical Industries, royalties from Neurostatus Systems GmbH, and grants from Bayer HealthCare, Biogen Idec, Merck Serono, Novartis, Roche, and Roche Research Foundations. AR serves on scientific advisory boards for Biogen Idec, Novartis, Genzyme, and OLEA Medical, has received speaker honoraria from Bayer HealthCare Pharmaceuticals, Genzyme, Bracco, Merck Serono, Teva Pharmaceutical Industries, OLEA Medical, Stendhal, Novartis, and Biogen Idec, and has research agreements with Siemens AG. JS-G has received compensation for serving on scientific advisory boards or on speaker's bureaus from Biogen Idec, Merck Serono, Novartis, Teva Pharmaceutical Industries, and Sanofi-Aventis. MT has received compensation for consulting services and speaker's fees from Bayer Schering, Merck Serono, Biogen Idec, Teva Pharmaceutical Industries, Sanofi-Aventis, and Novartis. JLF has served on scientific advisory boards for, and received funding of travel for participation in scientific advisory boards and honoraria from, Biogen Idec, Genzyme, Merck Serono, Novartis, Sanofi-Aventis, Takeda, and Teva Pharmaceutical Industries. CG has received compensation for consulting from Bayer HealthCare Pharmaceuticals and Biogen Idec and as a speaker for lectures from Biogen Idec, Bayer HealthCare Pharmaceuticals, Genzyme, Merck Serono, Novartis, and Teva Pharmaceutical Industries. JP reports personal fees from Biogen Idec, Teva Pharmaceutical Industries, Merck Serono, Bayer Schering, Novartis, Chugai Pharma, Ono Pharmaceuticals Co, and CI consulting, and grants from Merck Serono, Bayer Schering, and Novartis. DSR reports grants from Vertex Pharmaceuticals and patents PCT/US2012/067997 and PCT/US2013/033334 pending for development of lesion segmentation algorithms. BB serves as a centralised MRI reviewer for Novartis, and an unpaid advisor regarding paediatric multiple sclerosis clinical trial design for Novartis, Biogen Idec, and Teva Neuroscience. XM has received speaker's honoraria and travel expenses for scientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past 5 years with Actelion, Almirall, Bayer, Biogen Idec, Genzyme, Merck Serono, Novartis, Octapharma, Receptos, Roche, Sanofi-Genzyme, Teva Pharmaceutical Industries, and Trophos. FB serves as a scientific consultant to Bayer Schering Pharma, Sanofi-Aventis, Biogen Idec, Teva Pharmaceutical Industries, Merck Serono, Novartis, Roche, Synthon BV, Janssen, Genzyme, and Toshiba Medical systems, and has served on speakers’ bureaus for Serono Symposia Foundation and MedScape. Publisher Copyright: © 2016 Elsevier Ltd
PY - 2016
Y1 - 2016
N2 - In patients presenting with a clinically isolated syndrome, MRI can support and substitute clinical information in the diagnosis of multiple sclerosis by showing disease dissemination in space and time and by helping to exclude disorders that can mimic multiple sclerosis. MRI criteria were first included in the diagnostic work-up for multiple sclerosis in 2001, and since then several modifications to the criteria have been proposed in an attempt to simplify lesion-count models for showing disease dissemination in space, change the timing of MRI scanning to show dissemination in time, and increase the value of spinal cord imaging. Since the last update of these criteria, new data on the use of MRI to establish dissemination in space and time have become available, and MRI technology has improved. State-of-the-art MRI findings in these patients were discussed in a MAGNIMS workshop, the goal of which was to provide an evidence-based and expert-opinion consensus on proposed modifications to MRI criteria for the diagnosis of multiple sclerosis.
AB - In patients presenting with a clinically isolated syndrome, MRI can support and substitute clinical information in the diagnosis of multiple sclerosis by showing disease dissemination in space and time and by helping to exclude disorders that can mimic multiple sclerosis. MRI criteria were first included in the diagnostic work-up for multiple sclerosis in 2001, and since then several modifications to the criteria have been proposed in an attempt to simplify lesion-count models for showing disease dissemination in space, change the timing of MRI scanning to show dissemination in time, and increase the value of spinal cord imaging. Since the last update of these criteria, new data on the use of MRI to establish dissemination in space and time have become available, and MRI technology has improved. State-of-the-art MRI findings in these patients were discussed in a MAGNIMS workshop, the goal of which was to provide an evidence-based and expert-opinion consensus on proposed modifications to MRI criteria for the diagnosis of multiple sclerosis.
UR - http://www.scopus.com/inward/record.url?scp=84957812890&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84957812890&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(15)00393-2
DO - 10.1016/S1474-4422(15)00393-2
M3 - Review article
C2 - 26822746
AN - SCOPUS:84957812890
VL - 15
SP - 292
EP - 303
JO - The Lancet Neurology
JF - The Lancet Neurology
SN - 1474-4422
IS - 3
ER -